China Pharma Holdings (CPHI) Work In Process (2017 - 2024)

China Pharma Holdings (CPHI) has reported Work In Process for 8 consecutive years, with $334430.0 the latest figure, recorded in Q3 2024.

• For the quarter ending Q3 2024, Work In Process fell 50.59% year-over-year to $334430.0; the trailing twelve-month figure through Sep 2024 stood at $334430.0 (down 50.59% YoY), and the FY2023 full-year result was $413597.0, down 25.77% from the prior year.
• Work In Process climbed to $334430.0 in Q3 2024 per CPHI's latest filing, from $87308.0 in the prior quarter.
• Across five years, Work In Process topped out at $676885.0 in Q3 2023 and bottomed at $87308.0 in Q2 2024.
• Historically, Work In Process has averaged $431457.2 across 5 years, with a median of $423493.0 in 2020.
• The sharpest annual moves came in 2020 and 2024: Work In Process soared 110.99% in 2020, then tumbled 76.07% in 2024.
• Over 5 years, Work In Process stood at $662999.0 in 2020, then decreased by 15.97% to $557146.0 in 2021, then changed by 0.0% to $557146.0 in 2022, then dropped by 25.77% to $413597.0 in 2023, then slipped by 19.14% to $334430.0 in 2024.
• According to Business Quant data, Work In Process over the past three periods registered $334430.0, $87308.0, and $242726.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.